In Vivo Characterization of a Novel -Secretase Inhibitor SCH 697466 in Rodents and Investigation of Strategies for Managing Notch-Related Side Effects
International Journal of Alzheimer's Disease · 2013 · 2013 · 1-14
DOI: 10.1155/2013/823528 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Alzheimer's Disease, 2013. Verfasst von Lynn A Hyde und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Merck Research Laboratories, Kenilworth, NJ 07033, USA. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Abstract (Originalsprache)
Substantial evidence implicates -amyloid (A) peptides in the etiology of Alzheimer’s disease (AD). A is produced by the proteolytic cleavage of the amyloid precursor protein by - and -secretase suggesting that -secretase inhibition may provide therapeutic benefit for AD. Although many -secretase inhibitors have been shown to be potent at lowering A, some have also been shown to have side effects following repeated administration. All of these side effects can be attributed to altered Notch signaling, another -secretase substrate. Here we describe the in vivo characterization of the novel -secretase inhibitor SCH 697466 in rodents. Although SCH 697466 was effective at lowering A, Notch-related side effects in the intestine and thymus were observed following subchronic administration at doses that provided sustained and complete lowering of A. However, additional studies revealed that both partial but sustained lowering of Aand complete but less sustained lowering of A were successful approaches for managing Notch-related side effects. Further, changes in several Notch-related biomarkers paralleled the side effect observations. Taken together, these studies demonstrated that, by carefully varying the extent and duration of A lowering by -secretase inhibitors, it is possible to obtain robust and sustained lowering of A without evidence of Notch-related side effects.
Autor:innen und Institutionen
- Department of Neuroscience, Merck Research Laboratories, Kenilworth, NJ 07033, USA.
Zitieren
APA
Hyde, L. A., Zhang, Q., Del Vecchio, R. A., Leach, P. T., Cohen-Williams, M. E., Chen, L., Wong, G. T., McHugh, N. A., Chen, J., Higgins, G. A., Asberom, T., Li, W., Pissarnitski, D., Levitan, D., Nomeir, A. A., Clader, J. W., Zhang, L., & Parker, E. M. (2013). In Vivo Characterization of a Novel -Secretase Inhibitor SCH 697466 in Rodents and Investigation of Strategies for Managing Notch-Related Side Effects. International Journal of Alzheimer's Disease, 2013, 1-14. https://doi.org/10.1155/2013/823528
Vancouver
Hyde LA, Zhang Q, Del Vecchio RA, Leach PT, Cohen-Williams ME, Chen L, et al. In Vivo Characterization of a Novel -Secretase Inhibitor SCH 697466 in Rodents and Investigation of Strategies for Managing Notch-Related Side Effects. International Journal of Alzheimer's Disease. 2013;2013:1-14. doi:10.1155/2013/823528
BibTeX
@article{Hyde2013,
author = {Hyde, Lynn A and Zhang, Qi and Del Vecchio, Robert A and Leach, Prescott T and Cohen-Williams, Mary E and Chen, Lei and Wong, Gwendolyn T and McHugh, Nansie A and Chen, Joseph and Higgins, Guy A and Asberom, Theodros and Li, Wei and Pissarnitski, Dmitri and Levitan, Diane and Nomeir, Amin A and Clader, John W and Zhang, Lili and Parker, Eric M},
title = {In Vivo Characterization of a Novel -Secretase Inhibitor SCH 697466 in Rodents and Investigation of Strategies for Managing Notch-Related Side Effects},
journal = {International Journal of Alzheimer's Disease},
year = {2013},
volume = {2013},
pages = {1--14},
doi = {10.1155/2013/823528}
}
EUVIMED